What Is Sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal fragment of native Growth Hormone Releasing Hormone (GHRH). FDA-approved in 1997 for diagnosis and treatment of GH deficiency in children (later withdrawn from the US market for commercial reasons), it remains widely used in anti-aging and research medicine as a GH secretagogue that stimulates endogenous GH release rather than replacing it.
Mechanism and Advantages Over Exogenous GH
Sermorelin binds to GHRH receptors on pituitary somatotroph cells, activating adenylyl cyclase and increasing intracellular cAMP to drive GH synthesis and secretion. Unlike exogenous GH, which bypasses pituitary regulation, Sermorelin-stimulated GH release remains subject to normal hypothalamic feedback: somatostatin continues to modulate the response, preserving the natural pulsatile GH architecture and protecting against receptor desensitization and side effects of sustained supra-physiological GH exposure.
Research Applications
Sermorelin is studied for adult GH deficiency, anti-aging body composition optimization, sleep quality improvement (GH pulses occur predominantly during slow-wave sleep), and post-surgical/post-injury recovery. It is frequently combined with Ipamorelin for synergistic GH release — the GHRH + GHRP combination being the most studied pairing in GH secretagogue research.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy
Thorner, M., Rochiccioli, P., Colle, M., et al., 1996, Journal of Clinical Endocrinology & Metabolism - Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
Corpas, E., Harman, S.M., Piñeyro, M.A., Roberson, R., Blackman, M.R., 1992, Journal of Clinical Endocrinology & Metabolism - Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Prakash, A., Goa, K.L., 1999, BioDrugs - Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker, R.F., 2006, Clinical Interventions in Aging - A potentially effective drug for patients with recurrent glioma: sermorelin
Chang, Y., Huang, R., Zhai, Y., et al., 2021, Annals of Translational Medicine - Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males
Sinha, D.K., Balasubramanian, A., Tatem, A.J., et al., 2020, Translational Andrology and Urology - Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men
Vittone, J., Blackman, M.R., Busby-Whitehead, J., et al., 1997, Metabolism - Growth hormone-releasing hormone therapy in growth hormone-deficient children: Geref International Study Group
Geref International Study Group, 1996, Journal of Pediatric Endocrinology & Metabolism - Growth hormone secretagogues: history, mechanism of action, and clinical development
Ishida, J., Saitoh, M., Ebner, N., et al., 2020, JCSM Rapid Communications - Sermorelin acetate discontinuation - manufacturing, not safety related
FDA Center for Drug Evaluation and Research, 2013, FDA Communication - Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis
Otin J, Tran NT, Benoit A, 2023, Electrophoresis - A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Coutinho LFD, DE Oliveira Neves LF, Camilo RP, 2026, J Sports Med Phys Fitness - Probing for peptidic drugs (2-10 kDa) in doping control blood samples
Thomas A, Thilmany S, Hofmann A, 2022, Anal Sci Adv - Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples
Thomas A, Walpurgis K, Thevis M, 2024, J Mass Spectrom - The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, Rękoś Z, Olejarz M, 2026, Front Endocrinol (Lausanne)